Filing Details

Accession Number:
0001387131-23-003381
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2023-03-13 18:27:25
Reporting Period:
2023-03-08
Accepted Time:
2023-03-13 18:27:25
Original Submission Date:
2023-03-08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1599298 Summit Therapeutics Inc. SMMT () 4/A
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1507650 Mahkam Zanganeh C/O Summit Therapeutics Inc.
2882 Sand Hill Road, Suite 106
Menlo Park CA 94025
Co-Ceo & President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-03-08 16,778,415 $1.05 24,573,798 No 4 P Indirect By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee.
Common Stock Acquisiton 2023-03-08 6,748,629 $1.05 9,884,095 No 4 P Indirect By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee.
No 4 P Indirect By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee.
Footnotes
  1. Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering.
  2. Includes the number of shares of Common Stock that were inadvertently previously disclosed as being held by Dr. Zanganeh personally, which are held by the Mahkam Zanganeh Revocable Trust. Dr. Zanganeh does not directly hold any shares personally, all of her shares are held through the Mahkam Zanganeh Revocable Trust.
  3. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.